We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LabCorp® Announces a Personalized Drug Response Interpretation Service
Product News

LabCorp® Announces a Personalized Drug Response Interpretation Service

LabCorp® Announces a Personalized Drug Response Interpretation Service
Product News

LabCorp® Announces a Personalized Drug Response Interpretation Service


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "LabCorp® Announces a Personalized Drug Response Interpretation Service "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Laboratory Corporation of America® Holdings (LabCorp®) has announced that it has begun offering a personalized drug response interpretation service for cytochrome P450 (CYP450) testing called Signature Genetics™ to complement its expanding menu of genetic tests for CYP450 mutations.

The Signature Genetics™ service helps physicians use CYP450 genotyping information to make tailored treatment decisions based on an individual patient's CYP450 testing results.

A number of commonly prescribed drugs such as antidepressants, pain relievers, anticoagulants and cardiovascular agents are metabolized in the liver by CYP450.

Variants in CYP450 can cause medications to be ineffective or toxic, leading to significant side effects.

Using CYP450 genotyping to identify the variants is therefore an important step in the selection and prescribing of these medicines.

LabCorp currently offers CYP450 testing for 2C9, 2C19 and 2D6 variants, including Roche Diagnostics' Cytochrome AmpliChip™ P450 2D6/2C19 Genotyping and Phenotyping Assay.

The Signature Genetics™ CYP450 interpretation service can be ordered in addition to genotyping testing.

The service combines clinical data provided by the physician with genotyping provided by LabCorp to create a comprehensive, easy-to- read and actionable report.

The personalized report provides information on dosage adjustments the physician may consider to increase effectiveness of current treatments, and offers information on possible adverse drug interactions from concurrent treatments.

"The clinical value of CYP450 testing in therapy selection and dosing is widely documented, with more and more physicians now ordering these metabolism tests," said Myla P. Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp.

"With adverse drug reactions harming nearly two million patients annually, the dilemma has been finding a way to condense the complex genetic information generated by the testing into a straightforward form that physicians can use."

"The Signature Genetics™ service does just that, and we look forward to helping our clients better serve their patients with this new offering."

Advertisement